Cancer cell associated glycans as targets for immunotherapy

Therapeutic anti-glycan antibodies for cancer treatment are limited, in spite of the differential glycophenotype of cancer cells and associated biology. We have generated anti-Le glycan antibodies with clinical potential and multifaceted functionality. Increased understanding of all aspects of glyco...

Descripción completa

Detalles Bibliográficos
Autores principales: Vankemmelbeke, Mireille, Chua, Jia Xin, Durrant, Lindy G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760334/
https://www.ncbi.nlm.nih.gov/pubmed/26942075
http://dx.doi.org/10.1080/2162402X.2015.1061177
_version_ 1782416860412641280
author Vankemmelbeke, Mireille
Chua, Jia Xin
Durrant, Lindy G.
author_facet Vankemmelbeke, Mireille
Chua, Jia Xin
Durrant, Lindy G.
author_sort Vankemmelbeke, Mireille
collection PubMed
description Therapeutic anti-glycan antibodies for cancer treatment are limited, in spite of the differential glycophenotype of cancer cells and associated biology. We have generated anti-Le glycan antibodies with clinical potential and multifaceted functionality. Increased understanding of all aspects of glycomic research will ensure the continued development of glycan-targeted immunotherapeutics.
format Online
Article
Text
id pubmed-4760334
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-47603342016-03-03 Cancer cell associated glycans as targets for immunotherapy Vankemmelbeke, Mireille Chua, Jia Xin Durrant, Lindy G. Oncoimmunology Author's View Therapeutic anti-glycan antibodies for cancer treatment are limited, in spite of the differential glycophenotype of cancer cells and associated biology. We have generated anti-Le glycan antibodies with clinical potential and multifaceted functionality. Increased understanding of all aspects of glycomic research will ensure the continued development of glycan-targeted immunotherapeutics. Taylor & Francis 2015-07-15 /pmc/articles/PMC4760334/ /pubmed/26942075 http://dx.doi.org/10.1080/2162402X.2015.1061177 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Vankemmelbeke, Mireille
Chua, Jia Xin
Durrant, Lindy G.
Cancer cell associated glycans as targets for immunotherapy
title Cancer cell associated glycans as targets for immunotherapy
title_full Cancer cell associated glycans as targets for immunotherapy
title_fullStr Cancer cell associated glycans as targets for immunotherapy
title_full_unstemmed Cancer cell associated glycans as targets for immunotherapy
title_short Cancer cell associated glycans as targets for immunotherapy
title_sort cancer cell associated glycans as targets for immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760334/
https://www.ncbi.nlm.nih.gov/pubmed/26942075
http://dx.doi.org/10.1080/2162402X.2015.1061177
work_keys_str_mv AT vankemmelbekemireille cancercellassociatedglycansastargetsforimmunotherapy
AT chuajiaxin cancercellassociatedglycansastargetsforimmunotherapy
AT durrantlindyg cancercellassociatedglycansastargetsforimmunotherapy

Ejemplares similares